Q-omics provides the consensus-scored RNU1-16P profile across patient tissues and cancer cell-line models. RNU1-16P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, RNU1-16P is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, RNU1-16P RNA expression shows 13,640 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight READ, HNSC, and UVM as cancer lineages where RNU1-16P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU1-16P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU1-16P survival associations across molecular data types. RNU1-16P RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU1-16P RNA expression–survival associations across cancer types. High RNU1-16P expression shows unfavorable associations in LUSC, ESCA, UVM and HNSC, but favorable associations in READ and STAD. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .010). Together, the overview and detailed table identify READ as the clearest survival context for RNU1-16P RNA expression.
This table summarizes RNU1-16P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU1-16P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU1-16P shows higher tumor expression in HNSC, LIHC, STAD, PAAD and CHOL. The HNSC box plot shows higher RNU1-16P RNA expression in tumor versus normal tissue (log2 FC = +0.245, t-test p = .005).
This table shows molecular features associated with RNU1-16P in patient tissues and cancer cell lines. In patient samples, RNU1-16P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
